Drug Resistant Mycobacterium tuberculosis in Benue, Nigeria

Nwadioha, S. I.

doi:10.9734/bmrj/2014/9084

Cited by 20 publications

(19 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of rifampicin-resistant M. tuberculosis in this study was in keeping with previous studies in Nigeria [28], North India [29], Iran [30] and Northeast China [25]. However, it was higher than studies observed in Ethiopia [8, 9, 31, 32], Kenya [33], Nigeria [34], Uganda [35] and South of Iraq [36].…”

Section: Discussionsupporting

confidence: 89%

Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

BackgroundPrevailing data on rifampicin-resistant M. tuberculosis is essential for early management of MDR-TB. Therefore, this study was conducted to determine the prevalence of rifampicin-resistant Mycobacterium tuberculosis and associated factors among presumptive TB cases in Debre Markos Referral Hospital, Ethiopia.MethodsA cross-sectional study was conducted from September 2014 to March 2015. Detection of M. tuberculosis and resistance to rifampicin was performed using Gene Xpert MTB/RIF assay. Data was collected using structured questionnaire by face to face interview. Logistic regression analysis was computed to determine the associated factors of rifampicin-resistant M. tuberculosis.ResultsA total of 505 presumptive TB patients included in the study. The prevalence of M. tuberculosis confirmed cases was 117 (23.2%) (95% CI 19.7–27%). It was higher among males (27.9%) than females (17.9%) (AOR: 2.17; CI 1.35–3.49). Of the 117 M. tuberculosis confirmed cases, 12 (10.3%) (95% CI 6.0–17.1%) were resistant to rifampicin. Rifampicin-resistant M. tuberculosis was noticed in 7 previously treated TB patients (17.1%) and 5 treatment naive patients (6.7%) (AOR: 4.16; CI 1.04–16.63). The prevalence of rifampicin-resistant M. tuberculosis was 6 (9.8%) and 6 (11.3%) in pulmonary and extra-pulmonary infections, respectively. Of the 30, MTB/HIV co-infection, 3 (10%) were rifampicin-resistant M. tuberculosis.ConclusionRifampicin-resistant M. tuberculosis is prevalent in both pulmonary and extra-pulmonary tuberculosis patients. Previous treatment with anti-TB drugs was significantly associated with rifampicin resistance. Therefore, the use of Gene Xpert should be scaled up across the country for rapid detection and management of drug resistant M. tuberculosis.

show abstract

Section: Discussionsupporting

confidence: 89%

Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The RIF resistance prevalence of 2.9% in 10.3% of MTB detected cases found in this study is contrary to Nwadioha study which had a prevalence of RIF resistance in the study as 13.9% (Retreated 11.3%; Treatment naïve 2.6%) in 21.5% of MTB detected cases, the treatment naive RIF resistance prevalence [22] however, is similar with this present study.…”

Section: Discussionsupporting

confidence: 56%

Molecular Detection of Mycobacterium tuberculosis (MTB) and Rifampicin Resistant Strain among Subjects Accessing Health Care at Federal Medical Centre, Yenegoa, Bayelsa State; Nigeria

Obioma¹,

Ihua²,

Kpomasiruchi³

2017

Transl Biomed

View full text Add to dashboard Cite

Background: An increasing global incidence of Mycobacterium Tuberculosis (MTB), and emergence of drug resistant strains of MTB, have critically promoted the urgent need to explore better effective methods that can rapidly detect MTB, and identify drug-resistant cases as recommended by World Health Organization report of 2008. Globally, multi-drug-resistant strains of MTB are increasingly becoming a huge public health issue, which has adversely affected the health care delivery of patients, especially in developing communities with limited functioning health care facility. Nonetheless, the aim and focus of the study is to evaluate the trend of rifampicin resistance strains of MTB among patients accessing care at the Federal Medical Centre Yenegoa, Bayalsa State.

show abstract

“…An earlier study by Nwadioha et al, 2014 in two different hospitals in Makurdi in 2012 found the prevalence rate of GeneXpert/RIF positive pulmonary tuberculosis of 21.5% which is similar indicating reliability of the machine (Nwadioha et al, 2014). The current national prevalence of tuberculosis for Nigeria is 332/100,000.…”

Section: Resultsmentioning

confidence: 86%

GeneXpert MTB/RIF Sputum MTB Detection and Human Immunodeficiency Virus Seroprevalence among Patients with Presumptive Pulmonary Tuberculosis at a New Teaching Hospital in North-Central Nigeria

Mbaave¹,

Igbudu²,

Egwuda³

et al. 2016

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Drug Resistant Mycobacterium tuberculosis in Benue, Nigeria

Cited by 20 publications

References 8 publications

Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study

Rifampicin-resistance pattern of Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study

Molecular Detection of Mycobacterium tuberculosis (MTB) and Rifampicin Resistant Strain among Subjects Accessing Health Care at Federal Medical Centre, Yenegoa, Bayelsa State; Nigeria

GeneXpert MTB/RIF Sputum MTB Detection and Human Immunodeficiency Virus Seroprevalence among Patients with Presumptive Pulmonary Tuberculosis at a New Teaching Hospital in North-Central Nigeria

Contact Info

Product

Resources

About